Drug Profile
Metronidazole/minocycline - Yuhan Corporation
Alternative Names: Metronidazole + Minocycline - Yuhan; YH-26153Latest Information Update: 18 Apr 2019
Price :
$50
*
At a glance
- Originator Yuhan
- Class Amides; Anti-inflammatories; Antiacnes; Antibacterials; Antiprotozoals; Dimethylamines; Eye disorder therapies; Neuroprotectants; Nitroimidazoles; Radiosensitisers; Skin disorder therapies; Small molecules; Tetracyclines
- Mechanism of Action DNA synthesis inhibitors; Glial cell inhibitors; Interleukin 1 alpha inhibitors; Interleukin-6 modulators; Protein 30S ribosomal subunit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Peri-implantitis
Most Recent Events
- 18 Apr 2019 Chemical structure information added
- 09 Apr 2019 Discontinued - Phase-I for Peri-implantitis in South Korea (Yuhan Corporation pipeline, April 2019)
- 24 Nov 2017 Phase-I clinical trials in Peri-implantitis in South Korea before November 2017 (Yuhan Corporation pipeline, November 2017)